Pentixapharm Holding AG (XTER:PTP) Cash And Cash Equivalents : €23.23 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Pentixapharm Holding AG Cash And Cash Equivalents?

Pentixapharm Holding AG's quarterly cash and cash equivalents increased from Dec. 2023 (€9.70 Mil) to Jun. 2024 (€11.92 Mil) and increased from Jun. 2024 (€11.92 Mil) to Dec. 2024 (€23.23 Mil).

Pentixapharm Holding AG's annual cash and cash equivalents increased from Dec. 2022 (€1.09 Mil) to Dec. 2023 (€9.70 Mil) and increased from Dec. 2023 (€9.70 Mil) to Dec. 2024 (€23.23 Mil).

Pentixapharm Holding AG Cash And Cash Equivalents Historical Data

The historical data trend for Pentixapharm Holding AG's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pentixapharm Holding AG Cash And Cash Equivalents Chart

Pentixapharm Holding AG Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

2.39

1.09

9.70

23.23

Pentixapharm Holding AG Semi-Annual Data
	Dec21	Dec22	Jun23	Dec23	Jun24	Dec24
Cash And Cash Equivalents	Get a 7-Day Free Trial			1.09	-	9.70	11.92	23.23

Pentixapharm Holding AG Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Pentixapharm Holding AG (XTER:PTP) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Pentixapharm Holding AG Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Pentixapharm Holding AG's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Pentixapharm Holding AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pentixapharm Holding AG (XTER:PTP) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

PTPN:Austria

Address

Robert-Rossle-Street 10, Berlin, DEU

Website

https://www.pentixapharm.com

Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic.

Pentixapharm Holding AG Headlines

No Headlines